Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.

NCT00358566 is registered in ClinicalTrials.gov with Pharmexa A/S as lead sponsor.

NCT NCT00358566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00358566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"Primovax" - A Phase III Trial Comparing GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Advanced Un-Resectable Pancreatic Cancer.
Lead sponsor
Pharmexa A/S
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2006
Completion date
August 31, 2008
Enrollment
360 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

advanced unresectable pancreatic cancer